DNLI
Price
$13.67
Change
-$0.64 (-4.47%)
Updated
Jul 25 closing price
Capitalization
1.99B
5 days until earnings call
TLPPF
Price
$13.50
Change
-$0.44 (-3.16%)
Updated
Jul 25 closing price
Capitalization
4.69B
Interact to see
Advertisement

DNLI vs TLPPF

Header iconDNLI vs TLPPF Comparison
Open Charts DNLI vs TLPPFBanner chart's image
Denali Therapeutics
Price$13.67
Change-$0.64 (-4.47%)
Volume$1.18M
Capitalization1.99B
Telix Pharmaceutical
Price$13.50
Change-$0.44 (-3.16%)
Volume$8.09K
Capitalization4.69B
DNLI vs TLPPF Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. TLPPF commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and TLPPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (DNLI: $13.67 vs. TLPPF: $13.50)
Brand notoriety: DNLI and TLPPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 77% vs. TLPPF: 27%
Market capitalization -- DNLI: $1.99B vs. TLPPF: $4.69B
DNLI [@Biotechnology] is valued at $1.99B. TLPPF’s [@Biotechnology] market capitalization is $4.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileTLPPF’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • TLPPF’s FA Score: 1 green, 4 red.
According to our system of comparison, TLPPF is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while TLPPF’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • TLPPF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, TLPPF is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -2.36% price change this week, while TLPPF (@Biotechnology) price change was -15.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLPPF($4.7B) has a higher market cap than DNLI($1.99B). TLPPF YTD gains are higher at: -9.850 vs. DNLI (-32.924). TLPPF has higher annual earnings (EBITDA): 92.5M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. TLPPF (710M). DNLI has less debt than TLPPF: DNLI (48.6M) vs TLPPF (581M). TLPPF has higher revenues than DNLI: TLPPF (783M) vs DNLI (0).
DNLITLPPFDNLI / TLPPF
Capitalization1.99B4.7B42%
EBITDA-505.16M92.5M-546%
Gain YTD-32.924-9.850334%
P/E RatioN/A141.46-
Revenue0783M-
Total Cash818M710M115%
Total Debt48.6M581M8%
FUNDAMENTALS RATINGS
DNLI vs TLPPF: Fundamental Ratings
DNLI
TLPPF
OUTLOOK RATING
1..100
565
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
10023
SMR RATING
1..100
9474
PRICE GROWTH RATING
1..100
8564
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLPPF's Valuation (87) in the null industry is in the same range as DNLI (93) in the Biotechnology industry. This means that TLPPF’s stock grew similarly to DNLI’s over the last 12 months.

TLPPF's Profit vs Risk Rating (23) in the null industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that TLPPF’s stock grew significantly faster than DNLI’s over the last 12 months.

TLPPF's SMR Rating (74) in the null industry is in the same range as DNLI (94) in the Biotechnology industry. This means that TLPPF’s stock grew similarly to DNLI’s over the last 12 months.

TLPPF's Price Growth Rating (64) in the null industry is in the same range as DNLI (85) in the Biotechnology industry. This means that TLPPF’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as TLPPF (100) in the null industry. This means that DNLI’s stock grew similarly to TLPPF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLITLPPF
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
66%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
66%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
68%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLPPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DPREX12.88N/A
N/A
Macquarie Global Listed Real Assets A
VEMRX107.10N/A
N/A
Vanguard Emerging Mkts Stock Idx InsPlus
MUOSX32.19N/A
N/A
Morgan Stanley Instl US Core R6
LMVTX95.29N/A
N/A
ClearBridge Value C
FMURX28.90-0.06
-0.21%
Franklin Mutual International Value R

TLPPF and

Correlation & Price change

A.I.dvisor tells us that TLPPF and GLMD have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLPPF and GLMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLPPF
1D Price
Change %
TLPPF100%
-3.18%
GLMD - TLPPF
25%
Poorly correlated
+0.51%
DNLI - TLPPF
24%
Poorly correlated
-4.47%
BEAM - TLPPF
24%
Poorly correlated
+3.68%
RXRX - TLPPF
23%
Poorly correlated
+3.67%
JANX - TLPPF
23%
Poorly correlated
-0.04%
More